These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

6923 related articles for article (PubMed ID: 1500228)

  • 41. High proliferative capacity and specific antiautologous melanoma cytotoxicity of a human T-lymphocyte clone derived from tumor-infiltrating lymphocytes.
    Gervois N; Heuze F; Diez E; Jotereau F
    Hum Immunol; 1990 Jun; 28(2):112-8. PubMed ID: 2141008
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
    Wölfel T; Hauer M; Klehmann E; Brichard V; Ackermann B; Knuth A; Boon T; Meyer Zum Büschenfelde KH
    Int J Cancer; 1993 Sep; 55(2):237-44. PubMed ID: 7690346
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Novel approach to the characterization of melanoma associated-peptide-specific CTL lines from Japanese metastatic melanoma patients.
    Akiyama Y; Maruyama K; Tai S; Takikawa M; Ohshita C; Yamamoto A; Yamazaki N; Kiyohara Y; Yamaguchi K
    Int J Oncol; 2008 Sep; 33(3):433-41. PubMed ID: 18695871
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cytolytic T-cell clones against an autologous human melanoma: specificity study and definition of three antigens by immunoselection.
    Knuth A; Wölfel T; Klehmann E; Boon T; Meyer zum Büschenfelde KH
    Proc Natl Acad Sci U S A; 1989 Apr; 86(8):2804-8. PubMed ID: 2784858
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
    Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
    Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and downregulates HLA class I expression.
    Matsuda M; Salazar F; Petersson M; Masucci G; Hansson J; Pisa P; Zhang QJ; Masucci MG; Kiessling R
    J Exp Med; 1994 Dec; 180(6):2371-6. PubMed ID: 7964510
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas.
    Coulie PG; Brichard V; Van Pel A; Wölfel T; Schneider J; Traversari C; Mattei S; De Plaen E; Lurquin C; Szikora JP; Renauld JC; Boon T
    J Exp Med; 1994 Jul; 180(1):35-42. PubMed ID: 8006593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
    Rivoltini L; Kawakami Y; Sakaguchi K; Southwood S; Sette A; Robbins PF; Marincola FM; Salgaller ML; Yannelli JR; Appella E
    J Immunol; 1995 Mar; 154(5):2257-65. PubMed ID: 7868898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
    Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
    Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
    Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
    J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CD2/LFA-3 or LFA-1/ICAM-1 but not CD28/B7 interactions can augment cytotoxicity by virus-specific CD8+ cytotoxic T lymphocytes.
    de Waal Malefyt R; Verma S; Bejarano MT; Ranes-Goldberg M; Hill M; Spits H
    Eur J Immunol; 1993 Feb; 23(2):418-24. PubMed ID: 7679643
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2.
    Darrow TL; Abdel-Wahab Z; Quinn-Allen MA; Seigler HF
    Cell Immunol; 1996 Aug; 172(1):52-9. PubMed ID: 8806806
    [TBL] [Abstract][Full Text] [Related]  

  • 53. HLA-A2 presents shared tumor-associated antigens derived from endogenous proteins in ovarian cancer.
    Peoples GE; Goedegebuure PS; Andrews JV; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5481-91. PubMed ID: 8228240
    [TBL] [Abstract][Full Text] [Related]  

  • 54. IL-2 gene-transduced human HLA-A2 melanoma cells can generate a specific antitumor cytotoxic T-lymphocyte response.
    Guarini A; Gansbacher B; Cronin K; Fierro MT; Foa R
    Cytokines Mol Ther; 1995 Mar; 1(1):57-64. PubMed ID: 9384664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Multiple sub-sets of CD4+ and CD8+ cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles.
    Maccalli C; Mortarini R; Parmiani G; Anichini A
    Int J Cancer; 1994 Apr; 57(1):56-62. PubMed ID: 7908659
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Parainfluenza type 1 virus-infected cells are killed by both CD8+ and CD4+ cytotoxic T cell precursors.
    Slobod KS; Allan JE
    Clin Exp Immunol; 1993 Sep; 93(3):363-9. PubMed ID: 8396514
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3.
    Yang S; Kittlesen D; Slingluff CL; Vervaert CE; Seigler HF; Darrow TL
    J Immunol; 2000 Apr; 164(8):4204-11. PubMed ID: 10754316
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Generation of tumor-specific CTLs from melanoma patients by using peripheral blood stimulated with allogeneic melanoma tumor cell lines. Fine specificity and MART-1 melanoma antigen recognition.
    Stevens EJ; Jacknin L; Robbins PF; Kawakami Y; el Gamil M; Rosenberg SA; Yannelli JR
    J Immunol; 1995 Jan; 154(2):762-71. PubMed ID: 7814882
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Melanoma cell lysis by human CTL clones: differential involvement of T3, T8 and HLA antigens.
    Fossati G; Anichini A; Parmiani G
    Int J Cancer; 1987 Jun; 39(6):689-94. PubMed ID: 3108167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
    Somasundaram R; Robbins P; Moonka D; Loh E; Marincola F; Patel A; Guerry D; Herlyn D
    Int J Cancer; 2000 Jan; 85(2):253-9. PubMed ID: 10629086
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 347.